Efficacy of LAMA Added to ICS in Treatment of Asthma (ELITRA)

Exclusion criteria

• . Inability to carry out pulmonary lung function testing, to comply with study procedures or with study medication intake;
• . History of near fatal asthma or of a past hospitalisation for asthma in intensive care unit or of frequent exacerbations in the last year which, in the judgement of the Investigator, may have placed the patient at risk;
• . Hospitalisation, emergency room admission or use of systemic corticosteroids for asthma exacerbation in the 4 weeks prior to Screening visit or during the run-in period;
• . Lower respiratory tract infection in the 4 weeks before Screening visit or during the run-in period;
• . Patients who were in current therapy for gastroesophageal reflux disease (GERD) or patients with a medical history of GERD that led to asthma symptoms;
• . Patients with a seasonal worsening of asthma and who were not able to complete the study outside the relevant allergen season;
• . History of cystic fibrosis, bronchiectasis or alpha 1 antitrypsin deficiency, bronco carcinoma, lung carcinoma or any other significant lung disease which may have interfered with data evaluation;
• . Patients with a medical history or current diagnosis of COPD as defined by the Global Initiative for chronic obstructive lung disease (GOLD) guidelines (2014);